Feinstein Institutes/Northwell Health to enroll patients in multiple COVID-19 clinical trials

The Feinstein Institutes for Medical Research, the research arm of Northwell Health, will announce the enrollment of three large-scale clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus. Feinstein Institutes researchers are teaming up with Gilead Sciences and Regeneron Pharmaceuticals to identify effective treatments for patients currently hospitalized in moderate and severe conditions with COVID-19 with the goal to improve recovery and speed discharge from hospitals. Speakers: Michael Dowling, president & CEO, Northwell Health Dr. Kevin J. Tracey, president & CEO, Feinstein Institutes for Medical Research Dr. Christina Brennan, vice president, Clinical Research, Feinstein Institutes David Weinreich, MD, Senior Vice President, Head of Global Clinical Development and Co-Head of Global Development at Regeneron. Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, nearly 800 outpatient facilities and more than 14,200 credentialed physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 72,000 employees — 17,000-plus nurses and 4,500 employed doctors, including members of Northwell Health Physician Partners — are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. Visit Subscribe to Northwell Health’s YouTube or head to our channel The Well - Facebook – Twitter - Instagram - LinkedIn -